Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Two choices of drugs that reduce CV risk in T2DM
Two choices of drugs that reduce CV risk in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Two choices of drugs that reduce CV risk in T2DM
- Prof. John Deanfield, MD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
CDMC 2018: Shifting gears in the management of diabetes and CVD
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
- Dr. Adie Viljoen, MD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The GLP1 landscape - refining our understanding
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The GLP1 landscape - refining our understanding
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
- Prof John E Deanfield